Sun Pharmaceutical (SUNPHARMA.NS)

Executive Summary

Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company headquartered in Mumbai, India, with operations in over 100 countries. The company develops, manufactures, and markets a broad portfolio of generic and branded formulations, as well as Active Pharmaceutical Ingredients (APIs), with a focus on cardiology, psychiatry, neurology, gastroenterology, diabetology, and oncology. Sun Pharma also maintains a presence in dermatology and ophthalmology via its subsidiary Taro Pharmaceutical. With a market capitalization of approximately $388.8 billion, the company is publicly traded on the National Stock Exchange of India (ticker: SUNPHARMA.NS). Its strategic direction emphasizes scale in generics, investment in complex generics, specialty products, and novel drug delivery systems. Sun Pharma's R&D pipeline includes 214 drug candidates, covering various stages from pre-clinical to Phase 3. The company's recent clinical trials span indications such as non-small cell lung cancer, nasopharyngeal carcinoma, acne vulgaris, cervical cancer, and basal cell carcinoma. While many trials are in early stages or recently completed, Sun Pharma's robust pipeline and global footprint position it well for sustained growth in the pharmaceutical sector.

Upcoming Catalysts (preview)

• 2028Phase 2 Data Readout for Garsorasib Combination in NSCLC40% success
• 2028Phase 2 Cervical Cancer Trial with Sacituzumab tirumotecan plus Iparomlimab30% success
• TBDPotential FDA Approval for Generic Trifarotene Cream (Acne Vulgaris)50% success